Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

The treatment of chronic hepatitis C has been revolutionized with the introduction of direct-acting antivirals (DAAs). However, some patients are not cured with first-line treatment. Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination of a polymerase inhibitor, an NS5A inhibitor, and a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Childs-Kean, Lindsey M, Brumwell, Natalie A, Lodl, Emma F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662169/
https://www.ncbi.nlm.nih.gov/pubmed/31413603
http://dx.doi.org/10.2147/IDR.S171338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662169/
https://www.ncbi.nlm.nih.gov/pubmed/31413603
http://dx.doi.org/10.2147/IDR.S171338

Ejemplares similares